Caxton Associates (New York)’s ADMA Biologics ADMA Stock Holding History

Caxton Associates (New York)’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	$884K	Sell	51,568 -24,280	-32%	-$457K	0.03%	238
2024 Q3	$1.52M	Sell	75,848 -130,879	-63%	-$2.04M	0.06%	175
2024 Q2	$2.31M	Sell	206,727 -182,464	-47%	-$1.53M	0.08%	135
2024 Q1	$2.57M	Buy	389,191 +369,498	+1,876%	+$2.02M	0.14%	98
2023 Q4	$89K	Buy	+19,693	New	+$72.9K	﹤0.01%	447
2023 Q3	–	Sell	-140,190	Closed	-$517K	–	391
2023 Q2	$517K	Sell	140,190 -64,729	-32%	-$240K	0.08%	264
2023 Q1	$678K	Sell	204,919 -30,256	-13%	-$105K	0.1%	211
2022 Q4	$912K	Buy	+235,175	New	+$725K	0.06%	126

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Caxton Associates (New York)'s ADMA Position: Q4 2024 in Review

Caxton Associates (New York) reduced its ADMA Biologics (ADMA) stake by 32% in Q4 2024, selling an estimated $457K and leaving 51,568 shares worth $884K. The position accounts for 0.03% of the portfolio, ranked #238.

Caxton Associates (New York) first reported a position in ADMA in Q4 2022 and has held it in 8 quarters since. The position peaked at $2.57M in Q1 2024. 322 funds tracked by Wall St. Rank hold ADMA as of Q4 2024.

Caxton Associates (New York) held 51,568 shares of ADMA Biologics worth $884K as of Q4 2024.
Caxton Associates (New York) sold 24,280 ADMA Biologics shares in Q4 2024, an estimated $457K.
ADMA Biologics made up 0.03% of Caxton Associates (New York)'s portfolio in Q4 2024, its #238 holding.
Caxton Associates (New York) first reported a position in ADMA Biologics in Q4 2022 and has held it in 8 quarters since.
Caxton Associates (New York)'s ADMA Biologics position peaked at $2.57M in Q1 2024.
322 funds tracked by Wall St. Rank held ADMA Biologics as of Q4 2024.

Based on Caxton Associates (New York)'s 13F filing for Q4 2024, filed 14 Feb 2025.